BWS Financial lowered the firm’s price target on Assertio Holdings to $4 from $6 and keeps a Buy rating on the shares ahead of the company reporting earnings on November 8. Ahead of the report, the firm is readjusting expectations for Indocin and minimizing the revenue potential from Indocin in its model, noting that it sees Rolvedon as the primary revenue generator going forward.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ASRT: